Fingolimod is an effective disease modifying therapy for multiple sclerosis (MS). Beyond its main action on peripheral lymphocytes, several noteworthy side effects have been demonstrated in vitro, among which modulation of neural excitability. Our aim was to explore cortical excitability in vivo in patients treated with fingolimod 0.5mg/day.
Landi, D., Vollaro, S., Pellegrino, G., Mulas, D., Ghazaryan, A., Falato, E., Pasqualetti, P., Rossini, P. M., Filippi, M., Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis, <<CLINICAL NEUROPHYSIOLOGY>>, 2015; 126 (1): 165-169. [doi:10.1016/j.clinph.2014.05.031] [http://hdl.handle.net/10807/69801]
Autori: | |
Titolo: | Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.clinph.2014.05.031 |
Data di pubblicazione: | 2015 |
Abstract: | Fingolimod is an effective disease modifying therapy for multiple sclerosis (MS). Beyond its main action on peripheral lymphocytes, several noteworthy side effects have been demonstrated in vitro, among which modulation of neural excitability. Our aim was to explore cortical excitability in vivo in patients treated with fingolimod 0.5mg/day. |
Lingua: | Inglese |
Rivista: | |
Citazione: | Landi, D., Vollaro, S., Pellegrino, G., Mulas, D., Ghazaryan, A., Falato, E., Pasqualetti, P., Rossini, P. M., Filippi, M., Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis, <<CLINICAL NEUROPHYSIOLOGY>>, 2015; 126 (1): 165-169. [doi:10.1016/j.clinph.2014.05.031] [http://hdl.handle.net/10807/69801] |
Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |